 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Bristol-Myers Squibb Company (BMY) discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
It offers products in the following therapeutic classes: hematology, oncology, cardiovascular, and immunology. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with active RA and prostate-specific antigen, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis.
It also provides Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; and Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B.
In addition, it offers Reyataz, a protease inhibitor for the treatment of human immunodeficiency virus (HIV); Sustiva franchise, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV; and Daklinza NS5A replication complex inhibitor, Sunvepra NS3 protease inhibitor, and Beclabuvir NS5B inhibitor.
It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. The company has collaboration agreements with Pfizer; Otsuka; Ono; and Nektar.
Bristol-Myers Squibb reported Quarter December 2019 earnings of $1.22 per share on revenue of $7.9 billion. The consensus earnings estimate was $0.88 per share on revenue of $6.1 billion. Revenue grew 33.0% on a year-over-year basis.
The company said it expects 2020 earnings of $6.00 to $6.20 per share on revenue of $40.5 billion to $42.5 billion. The current consensus earnings estimate is $6.07 per share on revenue of $42.11 billion for the year ending December 31, 2020. The company also said it expects 2021 earnings of $7.15 to $7.45 per share. The current consensus earnings estimate is $7.18 per share for the year ending December 31, 2021.
The stock reports earnings on May 7th, 2020. The company should see a positive earnings report.
Entry point: $60.50
52-week trade range: $42.48 - $68.34
Stop/Loss: $57.00
Target Price: $67.00
BMY closed at $62.
